Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction — HECTOR  

Chronic Ischemic Left Ventricular Dysfunction Clinical Trial

Official title: A Phase I, Randomized Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes (hESC-CMs) in PaTients With ChrOnic Ischemic Left VentRicular Dysfunction Secondary to Myocardial Infarction (HECTOR)

Status Recruiting

Clinical Trial Summary

This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).

Clinical Trial Description

The phase I dose-escalation pilot study is intended as an initial safety assessment to establish the MTD prior to the phase II randomized, double-blinded, placebo-controlled study. An estimated eighteen (18) patients in phase I who are scheduled to undergo cardiac catheterization and have met all inclusion/exclusion criteria will be enrolled. ;

Related Conditions & MeSH terms

• Chronic Ischemic Left Ventricular Dysfunction
• Ischemia
• Ventricular Dysfunction
• Ventricular Dysfunction, Left

• NCT number: NCT05068674
• Study type: Interventional
• Source: Stanford University
• Contact: Joseph C. Wu, MD, PhD
• Phone: (650) 736-2246
• Email: joewu@stanford.edu
• Status: Recruiting
• Phase: Phase 1
• Start date: March 22, 2022
• Completion date: October 2025